Back to search
Cancer Therapy-related Cardiovascular Toxicity
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cancer Therapy-related Cardiovascular Toxicity trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Cancer Therapy-related Cardiovascular Toxicity trials you may qualify forCancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cance…
The BREATHS trial aims to investigate whether overnight in-bedroom air filtration reduces inflammation and cardiac biomarkers in adult survivors of cancer who a…
CAR-T cell or bispecific antibody therapies are a new treatment option for adult patients with aggressive forms of lymphoma or so-called plasma cell diseases ('…
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III…
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more…
The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, treated with cardiotoxic therapies.…
Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treat…
ATOPE-PRO, was developed with the intention of consolidating the integration of an innovative system for the prevention of cancer therapy-related cardiovascular…